All-In with Chamath, Jason, Sacks & Friedberg

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

September 29, 2025

Key Takeaways Copied to clipboard!

  • Eli Lilly's GLP-1 drug, Terzepatide (Mounjaro), became the best-selling drug in the world in Q2, generating $8.1 billion in revenue, stemming from research that began with a diabetes drug in 2006. 
  • Eli Lilly is committed to lowering the out-of-pocket cost for its GLP-1 drugs, aiming for single-digit deflation over time, but must balance this with the need to fund significant R&D (currently 25% of sales, or $14.2 billion this year) to create the next generation of medicines. 
  • GLP-1 drugs are showing unexpected pleiotropic effects, including helping with addictions like smoking and gambling, leading Eli Lilly to start clinical studies for mental health conditions like bipolar disorder and major depressive disorder. 

Segments

GLP-1 Success and Origin Story
Copied to clipboard!
(00:00:01)
  • Key Takeaway: Eli Lilly’s first GLP-1 drug launched in 2006, and the breakthrough molecule Terzepatide was created in 2014 by combining GLP-1 with another appetite-suppressing peptide.
  • Summary: The success of GLP-1 drugs is not overnight, tracing back to a twice-a-day diabetes injection launched in 2006. Terzepatide, the current blockbuster, was developed in 2014 by combining GLP-1 with a second appetite-suppressing peptide. Early trials for Terzepatide were stopped because healthy volunteers lost too much weight too quickly.
Counterfeit Drugs and Pricing Pressure
Copied to clipboard!
(00:05:11)
  • Key Takeaway: The high demand and insurance gaps for non-diabetic use incentivize a gray market for counterfeit peptides, particularly in China, which Eli Lilly must contend with.
  • Summary: The active gray market for counterfeit peptides, especially from China, is driven by poor insurance coverage for weight loss drugs in the US. Eli Lilly has reduced the out-of-pocket cost for its branded drug from $1,000 to $4.99 for eligible patients. The company expects single-digit deflation in the category over time but warns that cutting prices too low would eliminate the incentive for future R&D.
Capital Allocation Strategy
Copied to clipboard!
(00:09:08)
  • Key Takeaway: Eli Lilly prioritizes reinvesting cash flow into organic R&D (spending $14.2 billion this year) and building out US-based supply chains over simply returning all profits to shareholders.
  • Summary: Unlike companies that might return all cash flow after a patent expires, Lilly aims to create solutions for other problems, investing heavily in its 4,200 PhD scientists. A major capital focus is building six (with four more planned) US manufacturing plants to secure supply chain durability for injectables. The company also actively acquires external innovation, making deals about every two weeks.
Biotech VC Market Collapse
Copied to clipboard!
(00:12:45)
  • Key Takeaway: Biotech funding has cratered from $20 billion annually to around $5 billion due to competition from AI, an oversupply of public IPOs trading below cash, and aggressive ‘patent hacking’ by Chinese firms.
  • Summary: Biotech venture funding has collapsed as investors are crowded out by faster-return opportunities like AI. Many publicly traded biotechs are trading at or below cash, making general investment risky. Chinese entities are adept at ‘patent hacking’ by using AI to design chemically similar molecules outside the scope of existing US patents.
CEO Health Regimen and GLP-1 Longevity
Copied to clipboard!
(00:15:33)
  • Key Takeaway: Dave Ricks attributes his health to foundational habits—sleep, movement, healthy diet, and social relationships—and suggests low-dose GLP-1s may become a prophylactic for those over 60.
  • Summary: Ricks’ personal health routine focuses on sleep, movement, healthy eating (mostly plants), and social connections, which he believes are the four most important evidence-based factors for longevity. He has not used GLP-1s prophylactically yet, but anticipates that as safety is proven, low doses may become advisable for general use, especially for those over 60.
Unexpected GLP-1 Effects and Mental Health
Copied to clipboard!
(00:18:33)
  • Key Takeaway: GLP-1s have shown an immediate, unpredicted effect in reducing addictive behaviors like smoking and gambling, prompting studies into using tailored GLP-1s for bipolar disorder and major depressive disorder.
  • Summary: Beyond weight and blood sugar, GLP-1s immediately caused patients in studies to stop smoking, reduce gambling, and curb online shopping. Eli Lilly is now starting studies using a different GLP-1 variant, potentially with less weight loss but more brain activity, targeting severe mental health conditions. This addresses a major area of human suffering where current treatments like SSRIs are not fully solvent.
Media Influence and AI in Research
Copied to clipboard!
(00:21:51)
  • Key Takeaway: Dave Ricks supports reducing direct drug advertising on media platforms, noting current TV ads are poorly constructed due to 1992 FDA regulations, and views patient research using LLMs like ChatGPT as a ‘huge plus’.
  • Summary: Ricks would prefer less drug advertising, suggesting the money should go to R&D, and notes current TV ads are awkward because they must adhere to 1992 print regulations. He actively uses LLMs like ChatGPT to audit information about Eli Lilly’s drugs, finding the output substantially more accurate over the last two years. He believes empowered patients bringing deeper research to busy primary care doctors is a net positive for healthcare.
NIH Funding and Future Breakthroughs
Copied to clipboard!
(00:25:28)
  • Key Takeaway: The next major surprise breakthrough category is likely to be in brain diseases, as 40% of global human suffering stems from these conditions where current drug development has largely failed.
  • Summary: NIH funding cuts are difficult to predict the impact of, but Ricks supports transparency in the granting process to ensure it targets areas the market cannot solve alone, like landmark projects such as mapping the human genome. He suggests universities might not be the sole correct model for future research. The next major surprise category is predicted to be brain diseases, given the high rates of depression and dementia globally.